Allogene schedules Q3 results and autoimmune therapy data release
Allogene Therapeutics (ALLO) will report Q3 2026 results on November 5, followed by a conference call. On November 9, it will present preliminary safety and efficacy data from its Phase 1 RESOLUTION study of ALLO-329, an investigational CAR T therapy for autoimmune diseases, at the ACR Convergence meeting. The company develops allogeneic CAR T cell products for cancer and autoimmune diseases.
How this was made
The 30-second read
Why it matters
The earnings call and data webinar provide a catalyst for price movement; traders should watch guidance and safety/efficacy readouts.
Market read
Upcoming earnings and trial data create a near‑term catalyst for ALLO, with potential volatility but no immediate trade signal.
What to watch
Potential partnership or licensing announcements could accompany the data release.
Background
Allogene Therapeutics is a clinical‑stage biotech developing allogeneic CAR‑T therapies for cancer and autoimmune diseases.
Ticker impact
Allogene Therapeutics announced it will report Q3 2026 results on Nov 5, 2026 and present Phase 1 ALLO‑329 data on Nov 9, 2026.
potential pressure as the market prices in earnings guidance and trial data expectations
Investors will react to guidance and safety/efficacy signals; no new numbers are provided yet, so the move will depend on the results.
Market effects
May affect other allogeneic CAR‑T and biotech stocks awaiting trial data.
Limited to US biotech sector; no broader regional effect.
Low global impact; primarily relevant to investors in biotech and oncology pipelines.
Counterpoint
If the Phase 1 data are disappointing, the stock could rally on a short‑cover bounce.
Key entities
- companyAllogene Therapeutics, Inc.
Developer of allogeneic CAR‑T therapies, ticker ALLO.
- productALLO‑329
Dual anti‑CD19/anti‑CD70 CAR‑T candidate for autoimmune diseases.
